RxDoctor Payments Data

Waqas Ahmad, MD

Internal Medicine · Rockford, ILNPI 1316300247

Payments from drug & device makers

$1,519in general payments, 2019–2025

Across 19 payments — averaging $79.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$386
  • Boston Scientific$353
  • Inspire Medical Systems, Inc.$143
  • Beone Medicines USA, Inc.$143
  • Johnson & Johnson$125
  • Biohaven Pharmaceuticals, Inc.$124
  • plus $245 from 4 others

What the payments were for

  • Food & beverage$1,519100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,519 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$656,187
Medicare patients
468
Services billed
1,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$221,327
MounjaroTirzepatide170$214,178
OzempicSemaglutide170$206,344
JardianceEmpagliflozin128$139,584
TrulicityDulaglutide91$115,355
JanuviaSitagliptin Phosphate60$80,332
XareltoRivaroxaban60$65,861
RybelsusSemaglutide33$59,043
FarxigaDapagliflozin Propanediol39$49,041
Breo ElliptaFluticasone/Vilanterol48$29,261
MyrbetriqMirabegron41$28,468
Tresiba Flextouch U-200Insulin Degludec17$27,894
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog56$22,742
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,243
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$20,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$386$329,533261 claims
Novo NordiskOzempic, Rybelsus$25$265,387203 claims
Johnson & JohnsonXarelto$125$65,86160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →